PL346472A1 - High-affinity antibodies - Google Patents

High-affinity antibodies

Info

Publication number
PL346472A1
PL346472A1 PL99346472A PL34647299A PL346472A1 PL 346472 A1 PL346472 A1 PL 346472A1 PL 99346472 A PL99346472 A PL 99346472A PL 34647299 A PL34647299 A PL 34647299A PL 346472 A1 PL346472 A1 PL 346472A1
Authority
PL
Poland
Prior art keywords
affinity antibodies
antibodies
affinity
Prior art date
Application number
PL99346472A
Other languages
English (en)
Inventor
Peter John Harrison
Original Assignee
Ks Biomedix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ks Biomedix Ltd filed Critical Ks Biomedix Ltd
Publication of PL346472A1 publication Critical patent/PL346472A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL99346472A 1998-08-28 1999-08-20 High-affinity antibodies PL346472A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9818915.2A GB9818915D0 (en) 1998-08-28 1998-08-28 Antibodies
PCT/GB1999/002729 WO2000012556A1 (en) 1998-08-28 1999-08-20 High-affinity antibodies

Publications (1)

Publication Number Publication Date
PL346472A1 true PL346472A1 (en) 2002-02-11

Family

ID=10838074

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99346472A PL346472A1 (en) 1998-08-28 1999-08-20 High-affinity antibodies

Country Status (21)

Country Link
EP (1) EP1107990A1 (xx)
JP (1) JP2002525082A (xx)
KR (1) KR20010089174A (xx)
CN (1) CN1315966A (xx)
AU (1) AU5435099A (xx)
BG (1) BG105294A (xx)
BR (1) BR9913303A (xx)
CA (1) CA2340865A1 (xx)
EA (1) EA200100287A1 (xx)
GB (1) GB9818915D0 (xx)
HR (1) HRP20010149A2 (xx)
HU (1) HUP0103233A3 (xx)
ID (1) ID28905A (xx)
IL (1) IL141523A0 (xx)
MX (1) MXPA01002248A (xx)
NO (1) NO20011006L (xx)
PL (1) PL346472A1 (xx)
TR (1) TR200100643T2 (xx)
WO (1) WO2000012556A1 (xx)
YU (1) YU15401A (xx)
ZA (1) ZA200101573B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
GB0112844D0 (en) * 2001-05-25 2001-07-18 Psimei Pharmaceuticals Plc Neutron capture therapy
AU2003256266A1 (en) * 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
WO2005058236A2 (en) * 2003-12-12 2005-06-30 Genencor International, Inc. Cab molecules
CN111848790B (zh) * 2020-08-07 2022-02-22 上海交通大学 一种牛源抗金黄色葡萄球菌的单链抗体及其制备和应用
CN112724255A (zh) * 2021-01-28 2021-04-30 成都金昆生物科技有限公司 靶向癌胚抗原的小分子抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081235A (en) * 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method

Also Published As

Publication number Publication date
EA200100287A1 (ru) 2001-08-27
JP2002525082A (ja) 2002-08-13
TR200100643T2 (tr) 2001-07-23
KR20010089174A (ko) 2001-09-29
ID28905A (id) 2001-07-12
NO20011006D0 (no) 2001-02-27
MXPA01002248A (es) 2002-05-08
HUP0103233A2 (hu) 2001-12-28
BR9913303A (pt) 2001-10-09
AU5435099A (en) 2000-03-21
CA2340865A1 (en) 2000-03-09
HRP20010149A2 (en) 2002-02-28
NO20011006L (no) 2001-02-27
WO2000012556A1 (en) 2000-03-09
EP1107990A1 (en) 2001-06-20
YU15401A (sh) 2003-07-07
IL141523A0 (en) 2002-03-10
ZA200101573B (en) 2002-02-26
HUP0103233A3 (en) 2003-10-28
BG105294A (bg) 2001-12-29
CN1315966A (zh) 2001-10-03
GB9818915D0 (en) 1998-10-21

Similar Documents

Publication Publication Date Title
GB9809839D0 (en) Antibody
GB9603256D0 (en) Antibodies
GB9911569D0 (en) Antibodies
PL341642A1 (en) Novel macrolydes
EP1068213A4 (en) SILOXANES WITH AMINO-ORGANIC FUNCTIONAL GROUP
HK1039158A1 (zh) Nlk1相互作用蛋白
PL346472A1 (en) High-affinity antibodies
PL344979A1 (en) Angiostatin-binding protein
GB9828700D0 (en) Antibody
GB9816337D0 (en) Proteins
GB9828704D0 (en) Proteins
DE69923131D1 (en) Gyrator
GB9828880D0 (en) Protein
GB9825184D0 (en) Antigen
GB9819411D0 (en) Antibodies
GB9809566D0 (en) Protein
GB9819038D0 (en) Protein
GB9812607D0 (en) Protein
EP1127066A4 (en) MODIFIED PROTEINS
GB2335667B (en) Structural members
GB9800760D0 (en) Antigens
GB9816336D0 (en) Proteins
GB0315759D0 (en) Proteins
GB9816335D0 (en) Proteins
GB0212763D0 (en) Antibodies

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)